Result of AGM
("Nuformix" or the "Company")
Results of Annual General Meeting
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that all resolutions proposed at its Annual General Meeting held today were duly passed. The results are set out below:
The Q&A for AGM will be available on the website later this week.
Total votes cast
No. of votes
No. of votes
To receive the annual report and accounts for the year ended 31 March 2021
To approve the Remuneration Policy
To re-appoint Annual Report on Remuneration
To re-appoint Alastair Riddell as a director
To re-appoint Julian Gilbert as a director
To re-appoint s Madeleine Kennedy as a director
To re-appoint Anne Brindley as a director
To re-appoint haysmacintyre as auditor
To authorise the Directors to determine the auditor's fees.
To authorise the Directors to allot shares.
To authorise the Directors to disapply pre-emption rights.
To authorise the Company to purchase its own shares.
To authorise calling of a general meeting on 14 clear days' notice.
1 A vote withheld is not a vote under English law and is therefore not included in the calculation of votes for and against a resolution.
In accordance with Listing Rule 9.6.2, a copy of all resolutions passed as special business will
shortly be available for inspection at the National Storage Mechanism document viewing facility
Dr Alastair Riddell, Non-Executive Chairman
Dr Anne Brindley, CEO
Allenby Capital Limited
+44 (0) 20 3328 5656
Nick Athanas / George Payne (Corporate Finance)
Stefano Aquilino / Matt Butlin (Sales and Corporate Broking)
[email protected] or +44 (0)20 7933 8780
Anna Dunphy / Phillip Marriage / Kiki Zaccagnini
Tel: +44 (0)7876 741 001 / +44 (0)7980 541 893
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has an early-stage pipeline of preclinical and Phase 1-ready assets with potential for significant value and early licensing opportunities.
For more information, please visit www.nuformix.com.